- Home
- BMEA vs ORGN Comparison
BMEA vs ORGN Comparison
Compare BMEA & ORGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- ORGN
- Stock Information
- Founded
- BMEA 2017
- ORGN 2008
- Country
- BMEA United States
- ORGN United States
- Employees
- BMEA N/A
- ORGN N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- ORGN Major Chemicals
- Sector
- BMEA Health Care
- ORGN Industrials
- Exchange
- BMEA Nasdaq
- ORGN Nasdaq
- Market Cap
- BMEA 65.8M
- ORGN 72.7M
- IPO Year
- BMEA 2021
- ORGN N/A
- Fundamental
- Price
- BMEA $1.81
- ORGN $0.43
- Analyst Decision
- BMEA Strong Buy
- ORGN Strong Buy
- Analyst Count
- BMEA 10
- ORGN 1
- Target Price
- BMEA $22.30
- ORGN $3.00
- AVG Volume (30 Days)
- BMEA 5.2M
- ORGN 854.9K
- Earning Date
- BMEA 07-30-2025
- ORGN 08-13-2025
- Dividend Yield
- BMEA N/A
- ORGN N/A
- EPS Growth
- BMEA N/A
- ORGN N/A
- EPS
- BMEA N/A
- ORGN N/A
- Revenue
- BMEA N/A
- ORGN $29,887,000.00
- Revenue This Year
- BMEA N/A
- ORGN $49.18
- Revenue Next Year
- BMEA N/A
- ORGN $144.81
- P/E Ratio
- BMEA N/A
- ORGN N/A
- Revenue Growth
- BMEA N/A
- ORGN N/A
- 52 Week Low
- BMEA $1.29
- ORGN $0.40
- 52 Week High
- BMEA $13.07
- ORGN $1.90
- Technical
- Relative Strength Index (RSI)
- BMEA 44.35
- ORGN 38.07
- Support Level
- BMEA $2.24
- ORGN $0.42
- Resistance Level
- BMEA $3.08
- ORGN $0.47
- Average True Range (ATR)
- BMEA 0.40
- ORGN 0.03
- MACD
- BMEA -0.03
- ORGN 0.01
- Stochastic Oscillator
- BMEA 25.07
- ORGN 24.20
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.